Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Acta Neurológica Colombiana
Print version ISSN 0120-8748On-line version ISSN 2422-4022
Abstract
CRUCES MUNOZ, Paola Andrea. Intrathecal administration of baclofen in pregnancy: Case report. Acta Neurol Colomb. [online]. 2024, vol.40, n.3, e1824. Epub July 18, 2024. ISSN 0120-8748. https://doi.org/10.22379/anc.v40i3.1824.
Introduction:
Baclofen is an agonist of GABA receptors in the central nervous system (CNS) whose effect is to reduce spasticity. The dose used in intrathecal baclofen pump therapy is up to 100 times lower than oral. There are reports of withdrawal syndrome in neonates exposed to baclofen in utero.
Case presentation:
The case of a 31-year-old patient with a history of spasticity secondary to neonatal hypoxia being managed with an intrathecal baclofen pump since 2012 is presented, who in 2023 had a pregnancy, cesarean section at 37+2 weeks of gestation under general anesthesia with no complications with favorable maternal-fetal outcomes.
Discussion:
It is necessary to evaluate the safety of the use of technologies such as intrathecal pumps in pregnancy, in this case with the use of baclofen with which we found multiple questions given the absence of randomized studies such as its possible teratogenic effect on the fetus and the possible syndrome of abstinence on the neonate, the present clinical case reports the use of this technology with favorable maternal-fetal outcomes and compares it with the cases reported in the literature, also finding possible related side effects.
Conclusions:
The information to date seems to demonstrate that the use of baclofen intrathecally during pregnancy is completely safe given its low plasma concentrations.
Keywords : Botox; Botulinum toxin type A; Herpes zoster; Neuropathic pain; Postherpetic neuralgia; Tri-geminal neuralgia.